Physician profile
Stacy E Whitelock
NPI 1497886048
$6,051.27
in general payments reported to CMS, 2019-2025
24 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $377 · 2021: $728 · 2022: $1,059 · 2023: $1,210 · 2024: $1,001 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.58 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.10 | 2022-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $900.31 | 2021-2025 | Dupixent |
| Amgen INC. | $756.29 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $595.71 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $523.00 | 2019-2025 | |
| Incyte Corporation | $494.54 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $482.42 | 2022-2025 | Tremfya |
| Leo Pharma INC. | $174.80 | 2019-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $163.69 | 2019-2025 | Nemluvio |
| Celgene Corporation | $125.05 | 2019 | |
| Dermavant Sciences, INC. | $122.93 | 2023-2024 | Vtama |
| Genzyme Corporation | $107.96 | 2019-2022 | |
| Lilly USA, LLC | $107.52 | 2020-2023 | Olumiant, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.71 | 2019-2021 | |
| Kyowa Kirin, INC. | $84.66 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $77.18 | 2019-2021 | |
| Organon LLC | $53.81 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $45.89 | 2019 | |
| Sun Pharmaceutical Industries INC. | $38.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.89 | 2024 | Spevigo |
| Almirall LLC | $23.29 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.62 | 2023 | |
| Botanix Sb INC | $17.33 | 2025 | Sofdra |
| Journey Medical Corporation | $7.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Whitelock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.